Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 3Peripheral Nervous System Diseases 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Stomatitis 2Stomach Neoplasms 2Pseudomyxoma Peritonei 2Ototoxicity 2Neurofibromatosis 1 2Neoplasms 2Liver Neoplasms 2Hearing Loss 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Weight Loss 1Ulcer 1Tongue Neoplasms 1Tomaculous neuropathy 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Renal Artery Obstruction 1Radiation-Induced Mucositis 1Radiation Pneumonitis 1Pulmonary Embolism 1Primary Myelofibrosis 1Primary Graft Dysfunction 1

Interventions

Cochlear Implants 1Aging 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hearing Loss, Sensorineural × Acetylcysteine × Clear all
NCT04291209 2023-09-06

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Sunnybrook Health Sciences Centre

Phase 1/2 Unknown
80 enrolled

Deafness, Ear Diseases, Hearing Loss, Sensorineural, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡